Immunome, Inc. (IMNM) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
IMNM Revenue Growth
IMNM Revenue Analysis (2018–2025)
As of May 8, 2026, Immunome, Inc. (IMNM) generated trailing twelve-month (TTM) revenue of $6.9 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, IMNM's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $14.0 million in 2023.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), AGEN (+10.4% YoY), and FATE (-51.2% YoY), IMNM has underperformed the peer group in terms of revenue growth. Compare IMNM vs RCUS →
IMNM Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| IMNMCurrent | $7M | -100.0% | - | -3228.8% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 MGNX | $150M | +0.8% | +8.9% | -48.7% |
IMNM Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $6.9M | -23.2% | $0 | - | $-224,113,000 | -3228.8% |
| 2024 | $9.0M | -35.5% | $9.0M | 100.0% | $-305,800,000 | -3382.4% |
| 2023 | $14.0M | - | $14.0M | 100.0% | $-109,530,000 | -781.4% |
| 2022 | $0 | - | $0 | - | $-36,901,000 | - |
| 2021 | $0 | - | $0 | - | $-25,204,000 | - |
| 2020 | $0 | - | $-755,000 | - | $-12,261,000 | - |
| 2019 | $0 | - | $-615,000 | - | $-10,348,000 | - |
| 2018 | $0 | - | $-521,000 | - | $-7,743,000 | - |
See IMNM's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs IMNM Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare IMNM vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonIMNM — Frequently Asked Questions
Quick answers to the most common questions about buying IMNM stock.
Is IMNM's revenue growth accelerating or slowing?
IMNM revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $7M. This reverses the prior growth trend.
What is IMNM's long-term revenue growth rate?
Immunome, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is IMNM's revenue distributed by segment?
IMNM reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.